Render Target: SSR
Render Timestamp: 2024-12-19T21:13:13.669Z
Commit: f2d32940205a64f990b886d724ccee2c9935daff
XML generation date: 2024-09-30 01:55:24.861
Product last modified at: 2024-12-17T18:54:46.474Z
Cell Signaling Technology Logo
1% for the planet logo
PDP - Template Name: Monoclonal Antibody
PDP - Template ID: *******c5e4b77
R Recombinant
Recombinant: Superior lot-to-lot consistency, continuous supply, and animal-free manufacturing.

Eps8 (D1X1L) Rabbit mAb #43114

Filter:
  • WB
  • IP
  • IHC

    Supporting Data

    REACTIVITY H M R
    SENSITIVITY Endogenous
    MW (kDa) 95
    Source/Isotype Rabbit IgG
    Application Key:
    • WB-Western Blotting 
    • IP-Immunoprecipitation 
    • IHC-Immunohistochemistry 
    Species Cross-Reactivity Key:
    • H-Human 
    • M-Mouse 
    • R-Rat 

    Product Information

    Product Usage Information

    Application Dilution
    Western Blotting 1:1000
    Immunoprecipitation 1:50
    Immunohistochemistry (Paraffin) 1:100

    Storage

    Supplied in 10 mM sodium HEPES (pH 7.5), 150 mM NaCl, 100 µg/ml BSA, 50% glycerol and less than 0.02% sodium azide. Store at –20°C. Do not aliquot the antibody.

    Protocol

    Specificity / Sensitivity

    Eps8 (D1X1L) Rabbit mAb recognizes endogenous levels of total Eps8 protein.

    Species Reactivity:

    Human, Mouse, Rat

    Source / Purification

    Monoclonal antibody is produced by immunizing animals with a synthetic peptide corresponding to residues surrounding Arg250 of human Eps8 protein.

    Background

    Epidermal growth factor receptor pathway substrate 8 (Eps8) is an adaptor protein and can be phosphorylated by several receptor tyrosine kinases including EGFR and Src (1,2). Eps8 is composed of an N-terminal PTB domain, followed by an SH3 domain and a C-terminal effector domain. Eps8 controls actin-based motility by capping the barbed end of actin and bundling actin subunits through its C-terminal effector domain (3,4). The C-terminal α hexlical structure of Eps8 interacts directly with actin to exert these capping and bundling functions (5). The actin capping activity requires the release of Eps8 autoinhibitory binding through SH3 domain interaction with an adaptor molecule, such as Abi-1 (6). This SH3 domain of Eps8 also binds to RN-tre to regulate the down stream Rab5-mediated endocytosis pathway (6). Eps8 functions by binding several receptor tyrosine kinases, such as EGFR or FGFR, to enhance receptor mediated mitogenic Rac signaling and Rab5 endocytosis (6,7). The effector region of Eps8 is necessary for this process. By association with Abi-1 and forming the Eps8/Abi-1/Sos-1 complex, Eps8 couples initial growth factor stimulation to actin motility and the Rac activation pathway (8,9). Eps8 has been shown to be important in the cellular function of filopodial protrusions, cell migration, microvilli formation, and focal adhesion (10-13). Research studies have demonstrated that through its involvement in actin related cellular functions, Eps8 plays a role in cancer cell growth, survival, motility, and invasiveness (14-18).
    1. Fazioli, F. et al. (1993) EMBO J 12, 3799-808.
    2. Gallo, R. et al. (1997) Oncogene 15, 1929-36.
    3. Disanza, A. et al. (2004) Nat Cell Biol 6, 1180-8.
    4. Disanza, A. et al. (2006) Nat Cell Biol 8, 1337-47.
    5. Hertzog, M. et al. (2010) PLoS Biol 8, e1000387.
    6. Lanzetti, L. et al. (2000) Nature 408, 374-7.
    7. Auciello, G. et al. (2013) J Cell Sci 126, 613-24.
    8. Scita, G. et al. (1999) Nature 401, 290-3.
    9. Innocenti, M. et al. (2003) J Cell Biol 160, 17-23.
    10. Welsch, T. et al. (2007) Cancer Lett 255, 205-18.
    11. Frittoli, E. et al. (2011) Immunity 35, 388-99.
    12. Zwaenepoel, I. et al. (2012) Mol Biol Cell 23, 1080-94.
    13. Maa, M.C. et al. (2007) J Biol Chem 282, 19399-409.
    14. Xu, M. et al. (2009) Endocrinology 150, 2064-71.
    15. Chen, Y.J. et al. (2008) Mol Cancer Ther 7, 1376-85.
    16. Yap, L.F. et al. (2009) Oncogene 28, 2524-34.
    17. Chen, H. et al. (2010) Cancer Res 70, 9979-90.
    18. Funato, Y. et al. (2004) Cancer Res 64, 5237-44.
    For Research Use Only. Not For Use In Diagnostic Procedures.
    Cell Signaling Technology is a trademark of Cell Signaling Technology, Inc.
    SignalStain is a registered trademark of Cell Signaling Technology, Inc.
    XP is a registered trademark of Cell Signaling Technology, Inc.
    All other trademarks are the property of their respective owners. Visit our Trademark Information page.